ARTIDIS Raises CHF 8.8 Million for Regulatory Approval and Clinical Studies in Europe and US
scroll south
Healthtech startup ARTIDIS just announced the successful closure of a CHF 8.8 million seed financing in two rounds securing early clinical validation and the next development phase towards market entry in 2021. The round was supported by family offices and private individuals from Switzerland and EU including BERNINA Bioinvest, Zurich and SMD MedicalTrade AG, Taegerwilen.
The funding will be used to advance the company’s healthtech platform into a large multi-centre clinical study together with the University Hospital Tuebingen (Germany), University Hospital Barcelona (Spain), and Texas Medical Center (Houston, US).
“The closure of this financing round and the successful recruitment of 545 patients in our first clinical study at the University Hospital Basel this year is a huge success. We are thankful for the support and trust of all our shareholders – together, we are opening a new chapter towards personalizing the patient journey.” said Dr. Marija Plodinec, CEO of ARTIDIS.
TOP 100 Swiss Startup 2019 ARTIDIS' team is committed to radically improving health outcomes by harnessing the power of nanotechnology and innovation. ARTIDIS™ is an innovative new nanotechnology tool for cancer diagnosis and treatment that seeks to improve people’s lives by dramatically reducing the time it takes to accurately diagnose breast cancer – from a period of days or weeks to as little as three hours —thereby substantially reducing anxiety and time lost. UniBasel's BioZentrum spin-off's product ARTIDIS™ will also improve lives by facilitating personalized treatments, based on precise measurements of the aggressiveness of the cancer and individuals’ specific medical data and histories.
